Summary
Boston Scientific Corporation (BSX) filed a Form 8-K on March 17, 2006, to report the filing of Amendment No. 1 to its Registration Statement on Form S-4 concerning the proposed acquisition of Guidant Corporation. This amendment includes unaudited pro forma financial statements as of and for the year ended December 31, 2005. These pro forma statements give effect to the Guidant acquisition, the divestiture of Guidant's vascular and endovascular businesses to Abbott Laboratories, and the related financing transactions. Investors should note that these pro forma statements are for informational purposes only and are not necessarily indicative of the combined company's actual financial position or results of operations had the transactions been completed at the indicated dates. They also do not project future financial performance. The pro forma adjustments are based on preliminary estimates and assumptions and are subject to revision as more information becomes available. The filing incorporates these pro forma statements as Exhibit 99.1, to be read in conjunction with the historical financial statements of both Boston Scientific and Guidant.
Key Highlights
- 1Boston Scientific (BSX) filed an 8-K reporting on its proposed acquisition of Guidant Corporation.
- 2An amendment to the Form S-4 Registration Statement (No. 333-131608) was filed, including updated financial information.
- 3The filing includes unaudited pro forma financial statements as of and for the year ended December 31, 2005.
- 4These pro forma statements reflect the combined entity after the Guidant acquisition, the sale of Guidant's vascular/endovascular businesses to Abbott, and associated financing.
- 5The pro forma statements are presented for informational purposes and are based on preliminary estimates and assumptions.
- 6Exhibit 99.1 contains the unaudited pro forma condensed consolidated financial statements.